Active Ingredient: fluticasone furoate, umeclidinium (as bromide) and vilanterol (trifenatate)
Consumer Medicine Information
The Consumer Medicine Information is a leaflet written for people who have been prescribed this product. This information is intended for use in Australia only and does not replace advice from a healthcare professional. You should discuss the CMI with your healthcare professional if you have any questions or concerns.
Download Trelegy Ellipta CMI (PDF-145KB)
The Product Information is intended to assist healthcare professionals make decisions about treatment options and provide advice on the appropriate use of a medicine to patients. This information only applies to GSK products available in Australia.